Zydus And Lupin Partner To Co-Market Semaglutide Injection In India For Diabetes And Obesity Care

Zydus Lifesciences Limited has signed a Licensing and Supply Agreement with Lupin Limited to broaden access to its innovative semaglutide injection (15 mg/3 ml) in India. The therapy will be delivered via a patient-friendly, reusable pen device, facilitating ease of administration for individuals managing metabolic disorders. The collaboration combines Zydus’ product development strengths with Lupin’s extensive commercial reach across the Indian market.

Under the agreement, Lupin receives semi-exclusive rights to co-market the semaglutide injection in India. The product will be sold under the brand names Semanext and Livarise by Lupin. Zydus will simultaneously commercialise the therapy under its own brands, SEMAGLYN, MASHEMA, and ALTERME, enabling wider patient access through multiple channels.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “Our lifechanging discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients’ needs and convenience at the core, the innovative pen device we are offering is designed to simplify therapy and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India.

As part of the partnership structure, Lupin will provide Zydus with upfront licensing fees along with milestone payments tied to the achievement of predefined commercial and regulatory goals. The arrangement aligns incentives for both companies while accelerating availability of advanced metabolic care therapies in India. Semaglutide is approved for adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. 

” Nilesh Gupta, Managing Director, Lupin, said, " Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India.” 

It can be prescribed as a standalone therapy when metformin is unsuitable due to intolerance or contraindications, or in combination with other antidiabetic medications.  In addition to glycemic control, semaglutide is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. It is prescribed for adults with obesity (BMI ≥30 kg/m²) or those who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.